Identifying and Managing NASH in High-Risk Populations

Identifying and Managing NASH in High-Risk Populations

Tuesday, January 29, 2019
Webinar -- 12:00 PM ET

Agenda

  • Defining and Evaluating NAFLD and NASH
    • Identifying patients at risk andunderstanding metabolic risk
    • To screen or not to screen?
  •  Diagnosis
    • When and whom to refer
    • Interpreting FIB-4, NFS, imaging, and biopsy reports
  • Management in Primary Care
    • Lifestyle management, medical treatment, and addressing comorbidities
  • Questions and Answers

Audience Event Link: https://event.webcasts.com/starthere.jsp?ei=1229382&tp_key=3609a2e786

Click on the link above to attend the presentation from your laptop, tablet or mobile device. Audio will stream through your selected device, so be sure to have headphones or your volume turned up. If on a computer, the viewer works best in Chrome, although will work with other internet browsers.

 

Faculty

Faculty
Saleh Ali Alqahtani, MBChB

Assistant Professor of Medicine
Department of Medicine
Medical Director, International Digestive & Liver Disease Services
Department of Gastroenterology and Hepatology
Johns Hopkins University
Baltimore, Maryland

Goal Statement
The goal of this program is to improve participants’ competence in identifying and managing fatty liver disease among individuals at elevated risk and to increase awareness of NAFLD and NASH to patients who are at high risk for both diseases.

Target Audience
This program is intended for physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare providers who provide care for individuals at elevated risk for fatty liver disease, including long-haul commercial drivers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Incorporate the latest data and expert guidance to identify and appropriately evaluate patients at risk for NAFLD
  • Apply appropriate methodology to diagnose and characterize NAFLD and identify patients at risk for NASH and/or fibrosis who should be referred for liver biopsy
  • Apply best practices in the management of patients with NAFLD/NASH based on guideline recommendations for lifestyle modification and medical treatment

Accreditation

PHYSICIAN CONTINUING MEDICAL EDUCATION

Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation
CCO designates this live activity or enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING PHARMACY EDUCATION
CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008176-0000-19-002-L01-P) Type of Activity: Knowledge

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.